MCID: RNL077
MIFTS: 46

Renal Fibrosis

Categories: Nephrological diseases

Aliases & Classifications for Renal Fibrosis

MalaCards integrated aliases for Renal Fibrosis:

Name: Renal Fibrosis 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050855

Summaries for Renal Fibrosis

MalaCards based summary : Renal Fibrosis is related to renal oncocytoma and nephronophthisis 20. An important gene associated with Renal Fibrosis is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Mycophenolate mofetil and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and heart, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Renal Fibrosis

Diseases related to Renal Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 renal oncocytoma 28.5 CCL2 CTGF HGF SMAD3 TGFB1
2 nephronophthisis 20 10.7
3 anhidrosis 10.6 BMP6 CTGF TGFB1
4 uterine inflammatory disease 10.6 REN SERPINE1
5 retinitis pigmentosa 17 10.5 AGTR1 CTGF TGFB1
6 idiopathic steroid-sensitive nephrotic syndrome with diffuse mesangial proliferation 10.5 BMP7 CTGF SMAD2
7 rheumatic myocarditis 10.4 BMP6 CTGF SMAD3 TGFB1
8 urticaria 10.4 SMAD2 SMAD3 TGFB1
9 epidermolysis bullosa simplex superficialis 10.4 CD36 CTGF TGFB1
10 physical urticaria 10.4 BMP6 CD36 CTGF
11 fibular aplasia ectrodactyly 10.4 AGTR1 REN TGFB1
12 salt and pepper syndrome 10.4 CD36 CTGF TGFB1
13 middle lobe syndrome 10.4 CCL2 CTGF SERPINE1 TGFB1
14 nervous system cancer 10.4 CD36 CTGF TGFB1
15 adenocarcinoma 10.3 AGTR1 NR3C2 REN
16 ureteral obstruction 10.3
17 cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorinural hearing loss 10.3 NR3C2 SERPINE1
18 malignant struma ovarii 10.3 AGTR1 BMP6 BMP7 TGFB1
19 calcinosis 10.3 CCL2 CTGF REN TGFB1
20 panuveitis 10.3 AGTR1 NR3C2 REN
21 prostate neuroendocrine neoplasm 10.3 AGTR1 REN TGFB1
22 renal clear cell carcinoma 10.2 AGTR1 NR3C2 REN
23 laryngostenosis 10.2 AGTR1 CD36 NR3C2
24 hepatic infarction 10.2 REN SERPINE1
25 twin-to-twin transfusion syndrome 10.2 SMAD3 SMAD7 TGFB1
26 survival motor neuron spinal muscular atrophy 10.2 CCL2 REN SERPINE1
27 marfan lipodystrophy syndrome 10.2 AGTR1 BMP6 CD36
28 miliaria 10.1 CDH1 CTGF
29 detrusor sphincter dyssynergia 10.1 CCL2 SMAD2 TGFB1
30 stroke, ischemic 10.1 AGTR1 BMP7 REN SERPINE1
31 pleural tuberculosis 10.0 AGTR1 REN SERPINE1
32 peripheral artery disease 10.0 AGTR1 CCL2 REN SERPINE1
33 hypertrichosis of eyelid 10.0 AGTR1 CCL2 CTGF NR3C2 TGFB1
34 acromesomelic dysplasia 10.0 SMAD2 SMAD3 SMAD7
35 kidney disease 9.9
36 hypertension, essential 9.9 AGTR1 NR3C2 REN SERPINE1
37 congenital methemoglobinemia 9.9 BMP6 CD36 SMAD2 SMAD3 TGFB1
38 patent foramen ovale 9.8 CTGF HGF TGFB1
39 neuropathy, hereditary sensory and autonomic, type vi 9.8 CCL2 CTGF HGF
40 ischemia 9.8
41 exudative vitreoretinopathy 1 9.8 CCL2 CTGF HGF TGFB1
42 glomerulonephritis 9.7
43 endotheliitis 9.7
44 lymphedema 9.7 CTGF HGF REN TGFB1
45 hypoxia 9.7
46 nephrotic syndrome, idiopathic, steroid-resistant 9.6 CTGF SMAD2 SMAD3 SMAD7 TGFB1
47 pyelonephritis 9.6
48 urethritis 9.6
49 alport syndrome 9.6
50 keratopathy 9.5 CD36 SMAD2 SMAD3 SMAD7 TGFB1

Graphical network of the top 20 diseases related to Renal Fibrosis:



Diseases related to Renal Fibrosis

Symptoms & Phenotypes for Renal Fibrosis

MGI Mouse Phenotypes related to Renal Fibrosis:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 NR3C2 REN RGCC SERPINE1 SMAD2 SMAD3
2 growth/size/body region MP:0005378 10.4 AGTR1 BMP6 BMP7 CD36 CDH1 CTGF
3 cellular MP:0005384 10.34 HGF MAPK8 NPHP4 NR3C2 SMAD2 SMAD3
4 hematopoietic system MP:0005397 10.29 AGTR1 BMP7 CD36 HGF MAPK8 NR3C2
5 homeostasis/metabolism MP:0005376 10.27 MAPK8 NR3C2 REN SERPINE1 SMAD2 SMAD3
6 embryo MP:0005380 10.26 BMP7 CDH1 CTGF HGF MAPK8 RGCC
7 immune system MP:0005387 10.25 AGTR1 BMP7 CCL2 CD36 CDH1 MAPK8
8 mortality/aging MP:0010768 10.22 CTGF HGF MAPK8 NR3C2 REN RGCC
9 digestive/alimentary MP:0005381 10.19 CTGF MAPK8 SMAD2 SMAD3 SMAD7 TGFB1
10 endocrine/exocrine gland MP:0005379 10.16 BMP7 CD36 CDH1 MAPK8 SMAD2 SMAD3
11 craniofacial MP:0005382 10.09 BMP7 CTGF MAPK8 SMAD2 SMAD3 SMAD7
12 integument MP:0010771 10.06 BMP7 CDH1 CTGF MAPK8 SERPINE1 SMAD2
13 nervous system MP:0003631 10 AGTR1 BMP7 CD36 MAPK8 NPHP4 NR3C2
14 liver/biliary system MP:0005370 9.91 CD36 HGF MAPK8 SERPINE1 SMAD2 SMAD3
15 renal/urinary system MP:0005367 9.85 SERPINE1 SMAD3 TGFB1 AGTR1 BMP7 CD36
16 reproductive system MP:0005389 9.65 BMP6 BMP7 CDH1 MAPK8 NPHP4 REN
17 vision/eye MP:0005391 9.23 CD36 CTGF MAPK8 NPHP4 SMAD2 SMAD3

Drugs & Therapeutics for Renal Fibrosis

Drugs for Renal Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 352)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
2
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
3
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
4
Daclizumab Approved, Investigational Phase 4 152923-56-3
5
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
7
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
8
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
9
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
11
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
12
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
13
Febuxostat Approved Phase 4 144060-53-7 134018
14
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068
15
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
16
Lactulose Approved Phase 4 4618-18-2 11333
17
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
18
Basiliximab Approved, Investigational Phase 4,Phase 3 152923-56-3, 179045-86-4
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
21
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
22
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
23
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2 32986-56-4 5496 36294
24
Furosemide Approved, Vet_approved Phase 4,Phase 3 54-31-9 3440
25
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
26
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
27
Fluvastatin Approved Phase 4 93957-54-1 1548972
28
Tazobactam Approved Phase 4 89786-04-9 123630
29
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
30
Verapamil Approved Phase 4 52-53-9 2520
31
Chlorthalidone Approved Phase 4 77-36-1 2732
32
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
33
Inulin Approved, Nutraceutical Phase 4 9005-80-5 24763
34 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
35
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
36
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1 1406-16-2
37
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 1 41294-56-8 5282181
38
Angiotensin II Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
39
Uric Acid Experimental, Investigational Phase 4 69-93-2 1175
40
Lactitol Investigational Phase 4,Phase 3 585-86-4 3871
41
Pirfenidone Investigational Phase 4,Phase 2,Phase 1 53179-13-8 40632
42 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
44 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
45 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Antifungal Agents Phase 4,Phase 3,Phase 2
47 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
48 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Cyclosporins Phase 4,Phase 3,Phase 2
50 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 298)

id Name Status NCT ID Phase Drugs
1 Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis Unknown status NCT01860183 Phase 4 Mycophenolate mofetil
2 Fibrosis in Renal Allografts Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
3 Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal Unknown status NCT00896012 Phase 4 Rapamune (sirolimus/rapamycin);Tacrolimus
4 Tacrolimus to Sirolimus Conversion for Delayed Graft Function Unknown status NCT00931255 Phase 4 Tacrolimus (FK506, Prograf);Sirolimus (Rapamune, Rapamycin)
5 Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology Unknown status NCT01510795 Phase 4 spironolactone
6 Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE) Unknown status NCT02154854 Phase 4 Tacrolimus targeted half-dose;Tacrolimus targeted plain dose
7 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant Unknown status NCT01239472 Phase 4 everolimus
8 Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients Unknown status NCT01111422 Phase 4 N-acetylcysteine
9 A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus Unknown status NCT01608412 Phase 4 Tacrolimus;Everolimus
10 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
11 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4 Spironolactone
12 The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity Unknown status NCT01602861 Phase 4 Spironolactone;placebo
13 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4 Febuxostat
14 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
15 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
16 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4 tacrolimus OD, mycophenolic acid, prednisolone
17 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
18 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
19 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4 Everolimus;mycophenolic acid
20 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
21 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
22 Safety of Gadovist in Renally Impaired Patients Completed NCT00828737 Phase 4 Gadobutrol (Gadovist, BAY86-4875)
23 Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist Completed NCT00744939 Phase 4 Gadopentetate dimeglumine (Magnevist, BAY86-4882)
24 Novartis Everolimus Transition Completed NCT02096107 Phase 4 Everolimus
25 Primovist / Eovist in Renally Impaired Patients Completed NCT00908596 Phase 4 Gadoxetic acid disodium (Primovist, BAY86-4873)
26 A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation Completed NCT00817687 Phase 4 mycophenolate mofetil [CellCept];mycophenolate mofetil [CellCept]
27 Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis Completed NCT01207245 Phase 4
28 Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients Completed NCT01046045 Phase 4 everolimus
29 Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI) Completed NCT00908310 Phase 4 Omniscan
30 Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant Completed NCT00188955 Phase 4 sirolimus
31 Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection Completed NCT00885820 Phase 4 Tacrolimus;MMF;Corticosteroids (Prednisone)
32 Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients. Completed NCT01681303 Phase 4 AST-120
33 Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure. Completed NCT00409942 Phase 4 Torasemide Prolonged Release;Furosemide
34 The Effects of Omega-3 Fatty Acids in Renal Transplantation Completed NCT01744067 Phase 4 Omega-3 fatty acids;Placebo
35 Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers Completed NCT00171262 Phase 4 Fluvastatin
36 Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF) Completed NCT00637143 Phase 4 Tacrolimus;Cyclosporine
37 Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. Completed NCT00968695 Phase 4 Albumin
38 Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Completed NCT02421120 Phase 4 Ceftolozane/Tazobactam
39 IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy Recruiting NCT02918409 Phase 4 Colistin;Tobramycin
40 Ferumoxytol Enhanced Magnetic Resonance Angiography in Chronic Kidney Disease Recruiting NCT02997046 Phase 4
41 Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients Recruiting NCT02284464 Phase 4 Prednisone withdrawal;Prednisone continuation
42 Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients Recruiting NCT01551212 Phase 4 Everolimus (RAD001) as add-on;tacrolimus group
43 Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease Recruiting NCT02752191 Phase 4 ferumoxytol;gadofosveset
44 A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule Recruiting NCT02929420 Phase 4 Xiaoru Sanjie capsules;Xiao Yao pills
45 Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation Recruiting NCT02067182 Phase 4 Dabigatran
46 Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation Active, not recruiting NCT01541176 Phase 4 Corticotherapy post-transplantation
47 Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD Active, not recruiting NCT02502981 Phase 4 Spironolactone;Chlortalidone
48 Roll-over After 3-year Trial for Tenofovir in Mild Chronic Hepatitis B Enrolling by invitation NCT02463019 Phase 4 Tenofovir Disoproxil Fumarate
49 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Not yet recruiting NCT02338635 Phase 4 Ursodeoxycholic Acid
50 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Not yet recruiting NCT03182699 Phase 4

Search NIH Clinical Center for Renal Fibrosis

Genetic Tests for Renal Fibrosis

Anatomical Context for Renal Fibrosis

MalaCards organs/tissues related to Renal Fibrosis:

39
Kidney, Liver, Heart, Lung, Bone, Endothelial, Testes

Publications for Renal Fibrosis

Articles related to Renal Fibrosis:

(show top 50) (show all 295)
id Title Authors Year
1
Periostin-binding DNA aptamer treatment attenuates renal fibrosis under diabetic conditions. ( 28819200 )
2017
2
Sinomenine Hydrochloride Attenuates Renal Fibrosis by Inhibiting Excessive Autophagy Induced by Adriamycin: An Experimental Study. ( 28798804 )
2017
3
H2S improves renal fibrosis in STZ-induced diabetic rats by ameliorating TGF-I^1 expression. ( 27882817 )
2017
4
BMP7-induced-Pten inhibits Akt and prevents renal fibrosis. ( 28923783 )
2017
5
Transcriptome Identified lncRNAs Associated with Renal Fibrosis in UUO Rat Model. ( 28912732 )
2017
6
Corrigendum to "Dual Inhibiting Senescence and Epithelial-to-Mesenchymal Transition by Erythropoietin Preserve Tubular Epithelial Cell Regeneration and Ameliorate Renal Fibrosis in Unilateral Ureteral Obstruction". ( 28567417 )
2017
7
Complement inhibition attenuates acute kidney injury after ischemia-reperfusion and limits progression to renal fibrosis in mice. ( 28832655 )
2017
8
Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats. ( 28860994 )
2017
9
Selective tubular activation of hypoxia-inducible factor-2I+ has dual effects on renal fibrosis. ( 28900259 )
2017
10
Role of Stat3 Signaling in Control of EMT of Tubular Epithelial Cells During Renal Fibrosis. ( 28848189 )
2017
11
NiaoDuQing granules relieve chronic kidney disease symptoms by decreasing renal fibrosis and anemia. ( 28915563 )
2017
12
Deficiency of mPGES-1 exacerbates renal fibrosis and inflammation in mice with unilateral ureteral obstruction. ( 27784694 )
2017
13
Baicalin and baicalein attenuate renal fibrosis in vitro via inhibition of the TGF-I^1 signaling pathway. ( 28928802 )
2017
14
Potential association between elevated serum human epididymis protein 4 and renal fibrosis: A systemic review and meta-analysis. ( 28885334 )
2017
15
Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis. ( 27855304 )
2017
16
Complement C5a receptors C5L2 and C5aR in renal fibrosis. ( 28903945 )
2017
17
Untargeted DNA-Demethylation Therapy Neither Prevents Nor Attenuates Ischemia-Reperfusion-Induced Renal Fibrosis. ( 28750405 )
2017
18
Lecru L, Desterke C, Grassin-Delyle S, etA al. Cannabinoid receptor 1 is a major mediator of renal fibrosis. Kidney Int. 2015;88:72-84. ( 28938941 )
2017
19
Potential involvement of Fgf10/Fgfr2 and androgen receptor (AR) in renal fibrosis in adult male rat offspring subjected to prenatal exposure to di-n-butyl phthalate (DBP). ( 28919491 )
2017
20
AMP-activated protein kinase/myocardin-related transcription factor-A signaling regulates fibroblast activation and renal fibrosis. ( 28739141 )
2017
21
Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. ( 28064215 )
2017
22
Psoralea corylifolia L. Seed Extract Attenuates Diabetic Nephropathy by Inhibiting Renal Fibrosis and Apoptosis in Streptozotocin-Induced Diabetic Mice. ( 28767064 )
2017
23
Yan Y, Ma L, Zhou X, et al. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Kidney Int. 2016;89:68-81. ( 28807271 )
2017
24
Intermedin attenuates renal fibrosis by induction of heme oxygenase-1 in rats with unilateral ureteral obstruction. ( 28697727 )
2017
25
Feature selection and classification of urinary mRNA microarray data by iterative random forest to diagnose renal fibrosis: a two-stage study. ( 28045061 )
2017
26
Klotho as a Therapeutic Target during the Development of Renal Fibrosis. ( 27951565 )
2017
27
A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis. ( 28933600 )
2017
28
PHF14: an innate inhibitor against the progression of renal fibrosis following folic acid-induced kidney injury. ( 28045076 )
2017
29
miR-410 suppresses the expression of interleukin-6 as well as renal fibrosis in the pathogenesis of lupus nephritis. ( 27028192 )
2016
30
Wnt6 regulates epithelial cell differentiation and is dysregulated in renal fibrosis. ( 27122540 )
2016
31
IL-17 mediates neutrophil infiltration and renal fibrosis following recovery from ischemia reperfusion:compensatory role of Natural Killer cells in athymic rats. ( 27852609 )
2016
32
Sinomenine attenuates renal fibrosis through Nrf2-mediated inhibition of oxidative stress and TGFI^ signaling. ( 27211841 )
2016
33
CD11ca8_ CD8a8_ T Cells Reduce Renal Fibrosis Following Ureteric Obstruction by Inducing Fibroblast Apoptosis. ( 28025478 )
2016
34
CD39 overexpression does not attenuate renal fibrosis in the unilateral ureteric obstructive model of chronic kidney disease. ( 27565966 )
2016
35
Effects of Bone Marrow Mesenchymal Stem Cells on Plasminogen Activator Inhibitor-1 and Renal Fibrosis in Rats with Diabetic Nephropathy. ( 27018336 )
2016
36
Protective role of activin receptor-like kinase 7 gene silencing in renal fibrosis. ( 27620491 )
2016
37
Hydroxysafflor Yellow A Ameliorates Renal Fibrosis by Suppressing TGF-I^1-Induced Epithelial-to-Mesenchymal Transition. ( 27088510 )
2016
38
The complement factor 5a receptor 1 has a pathogenic role in chronic inflammation and renal fibrosis in a murine model of chronic pyelonephritis. ( 27370410 )
2016
39
N-acetylcysteine alleviates angiotensin II-mediated renal fibrosis in mouse obstructed kidneys. ( 27041464 )
2016
40
Activation of FXR protects against renal fibrosis via suppressing Smad3 expression. ( 27853248 )
2016
41
MicroRNA-196a/b Mitigate Renal Fibrosis by Targeting TGF-I^ Receptor 2. ( 26940097 )
2016
42
HuangQi Decoction Ameliorates Renal Fibrosis via TGF-I^/Smad Signaling Pathway In Vivo and In Vitro. ( 27161221 )
2016
43
Whole-transcriptome analysis of UUO mouse model of renal fibrosis reveals new molecular players in kidney diseases. ( 27189340 )
2016
44
Numb contributes to renal fibrosis by promoting tubular epithelial cell cycle arrest at G2/M. ( 27016419 )
2016
45
Piceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK Signaling. ( 27902771 )
2016
46
Label-free fluorescence lifetime and second harmonic generation imaging microscopy improves quantification of experimental renal fibrosis. ( 27555119 )
2016
47
Mesenchymal Stromal Cells Prevent Renal Fibrosis in a Rat Model of Unilateral Ureteral Obstruction by Suppressing the Renin-Angiotensin System via HuR. ( 26866372 )
2016
48
Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension. ( 27986554 )
2016
49
Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Accelerates the Progression of Renal Fibrosis in Lupus Nephritis by Activating SMAD and p38 MAPK in TGF-I^1 Signaling Pathway. ( 27365897 )
2016
50
Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. ( 27165838 )
2016

Variations for Renal Fibrosis

Expression for Renal Fibrosis

Search GEO for disease gene expression data for Renal Fibrosis.

Pathways for Renal Fibrosis

Pathways related to Renal Fibrosis according to GeneCards Suite gene sharing:

(show all 47)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 BMP6 BMP7 CCL2 CDH1 CTGF HGF
2
Show member pathways
13.49 AGTR1 BMP6 BMP7 CCL2 CDH1 CTGF
3
Show member pathways
13.31 BMP6 BMP7 CCL2 CDH1 CTGF HGF
4
Show member pathways
13.27 BMP6 BMP7 CDH1 CTGF HGF MAPK8
5
Show member pathways
13.04 AGTR1 BMP6 BMP7 CCL2 CTGF HGF
6
Show member pathways
12.88 CCL2 MAPK8 SERPINE1 SMAD2 SMAD3 TGFB1
7 12.71 AGTR1 CDH1 HGF MAPK8 SMAD2 SMAD3
8
Show member pathways
12.69 BMP6 BMP7 CTGF HGF TGFB1
9
Show member pathways
12.48 BMP7 SMAD2 SMAD3 SPHK1 TGFB1
10 12.4 MAPK8 SMAD2 SMAD3 TGFB1
11 12.35 CDH1 SMAD2 SMAD3 TGFB1
12
Show member pathways
12.32 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
13 12.27 BMP6 BMP7 SERPINE1 SMAD2 SMAD3 TGFB1
14
Show member pathways
12.21 MAPK8 SMAD2 SMAD3 TGFB1
15 12.17 CDH1 SMAD2 SMAD3 TGFB1
16 12.1 MAPK8 SMAD2 SMAD3 SMAD7 TGFB1
17
Show member pathways
12.09 MAPK8 SMAD2 SMAD3 TGFB1
18 12.08 BMP6 BMP7 MAPK8 SMAD2 SMAD3 TGFB1
19 12.01 AGTR1 CDH1 CTGF SERPINE1 SMAD2 SMAD3
20 11.99 CCL2 CD36 HGF TGFB1
21 11.96 MAPK8 SMAD2 SMAD3 SMAD7 TGFB1
22
Show member pathways
11.88 SMAD2 SMAD3 TGFB1
23 11.86 BMP6 BMP7 TGFB1
24 11.86 CCL2 HGF REN TGFB1
25
Show member pathways
11.84 SMAD2 SMAD3 TGFB1
26 11.8 SERPINE1 SMAD2 SMAD3 SMAD7
27 11.77 BMP6 BMP7 SMAD2 SMAD3 SMAD7 TGFB1
28 11.75 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
29 11.74 BMP6 BMP7 CTGF HGF TGFB1
30
Show member pathways
11.74 SMAD2 SMAD3 SMAD7 TGFB1
31 11.72 CDH1 SMAD2 SMAD3
32
Show member pathways
11.72 BMP6 BMP7 SMAD7
33 11.7 AGTR1 CCL2 MAPK8 SERPINE1 SMAD2 SMAD3
34 11.67 MAPK8 SMAD2 SMAD3
35 11.66 BMP6 BMP7 TGFB1
36
Show member pathways
11.63 MAPK8 SMAD2 SMAD3 TGFB1
37 11.59 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
38 11.58 CCL2 CD36 HGF TGFB1
39 11.54 MAPK8 SMAD3 TGFB1
40 11.53 BMP7 CCL2 CTGF HGF SMAD7 TGFB1
41 11.51 CTGF SMAD2 SMAD3 SMAD7 TGFB1
42 11.46 BMP6 BMP7 CDH1 CTGF SERPINE1 SMAD2
43 11.33 HGF SMAD2 SMAD3 TGFB1
44 11.23 BMP6 BMP7 CCL2 HGF MAPK8
45 11.01 CDH1 SMAD2 SMAD3 TGFB1
46 10.83 AGTR1 CTGF MAPK8 SERPINE1 SMAD2 SMAD3
47 10.51 BMP6 SMAD7

GO Terms for Renal Fibrosis

Cellular components related to Renal Fibrosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.7 AGTR1 CCL2 MAPK8 REN SMAD2 SMAD3
2 extracellular space GO:0005615 9.61 BMP6 BMP7 CCL2 CD36 CTGF HGF
3 platelet alpha granule lumen GO:0031093 9.43 HGF SERPINE1 TGFB1
4 catenin complex GO:0016342 9.37 CDH1 SMAD7
5 SMAD protein complex GO:0071141 9.32 SMAD2 SMAD3
6 SMAD2-SMAD3 protein complex GO:0071144 8.62 SMAD2 SMAD3
7 cytoplasm GO:0005737 10.28 BMP6 CCL2 CDH1 MAPK8 NPHP4 NR3C2
8 extracellular region GO:0005576 10.06 BMP6 BMP7 CCL2 CDH1 CTGF HGF

Biological processes related to Renal Fibrosis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.98 CD36 CTGF SMAD2 TGFB1
2 positive regulation of cell migration GO:0030335 9.97 HGF SMAD3 SPHK1 TGFB1
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 CCL2 CD36 CTGF TGFB1
4 positive regulation of gene expression GO:0010628 9.93 CTGF MAPK8 RGCC SMAD2 SMAD3 TGFB1
5 response to organic substance GO:0010033 9.91 CDH1 REN TGFB1
6 cellular response to lipopolysaccharide GO:0071222 9.91 CCL2 CD36 MAPK8 SERPINE1
7 ossification GO:0001503 9.9 BMP6 BMP7 CTGF
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.9 CD36 HGF TGFB1
9 platelet degranulation GO:0002576 9.9 CD36 HGF SERPINE1 TGFB1
10 cellular response to mechanical stimulus GO:0071260 9.88 BMP6 MAPK8 TGFB1
11 response to wounding GO:0009611 9.88 CCL2 CTGF TGFB1
12 kidney development GO:0001822 9.88 AGTR1 BMP6 BMP7 REN
13 response to glucose GO:0009749 9.87 CTGF SMAD2 TGFB1
14 cell chemotaxis GO:0060326 9.87 AGTR1 CCL2 HGF
15 cellular response to transforming growth factor beta stimulus GO:0071560 9.84 SMAD3 SMAD7 TGFB1
16 BMP signaling pathway GO:0030509 9.84 BMP6 BMP7 SMAD7 TGFB1
17 positive regulation of osteoblast differentiation GO:0045669 9.83 BMP6 BMP7 HGF
18 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.83 SMAD2 SMAD3 SMAD7 TGFB1
19 transforming growth factor beta receptor signaling pathway GO:0007179 9.83 CCL2 SMAD2 SMAD3 SMAD7 TGFB1
20 positive regulation of stress fiber assembly GO:0051496 9.82 CTGF RGCC SMAD3
21 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.81 BMP6 BMP7 TGFB1
22 animal organ regeneration GO:0031100 9.81 CCL2 HGF TGFB1
23 epithelial to mesenchymal transition GO:0001837 9.79 BMP7 HGF TGFB1
24 mesoderm formation GO:0001707 9.78 BMP7 SMAD2 SMAD3
25 positive regulation of bone mineralization GO:0030501 9.78 BMP6 BMP7 SMAD3 TGFB1
26 endoderm development GO:0007492 9.77 SMAD2 SMAD3 TGFB1
27 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.76 BMP7 SPHK1 TGFB1
28 embryonic pattern specification GO:0009880 9.74 BMP7 SMAD2 SMAD3
29 wound healing GO:0042060 9.73 SMAD3 TGFB1
30 negative regulation of wound healing GO:0061045 9.73 SERPINE1 SMAD3
31 negative regulation of cell-cell adhesion GO:0022408 9.73 CDH1 TGFB1
32 lens fiber cell differentiation GO:0070306 9.72 SMAD3 TGFB1
33 pathway-restricted SMAD protein phosphorylation GO:0060389 9.72 SMAD7 TGFB1
34 positive regulation of DNA biosynthetic process GO:2000573 9.72 HGF RGCC
35 positive regulation of blood coagulation GO:0030194 9.72 CD36 SERPINE1
36 mesonephros development GO:0001823 9.71 BMP7 REN
37 positive regulation of SMAD protein import into nucleus GO:0060391 9.71 BMP6 TGFB1
38 positive regulation of cell-cell adhesion GO:0022409 9.71 CCL2 SMAD7
39 salivary gland morphogenesis GO:0007435 9.7 BMP7 TGFB1
40 primary miRNA processing GO:0031053 9.69 SMAD2 SMAD3
41 pericardium development GO:0060039 9.69 SMAD2 SMAD3
42 response to cholesterol GO:0070723 9.69 SMAD2 TGFB1
43 embryonic foregut morphogenesis GO:0048617 9.68 SMAD2 SMAD3
44 response to laminar fluid shear stress GO:0034616 9.68 SMAD7 TGFB1
45 SMAD protein complex assembly GO:0007183 9.67 SMAD2 SMAD3 TGFB1
46 nodal signaling pathway GO:0038092 9.66 SMAD2 SMAD3
47 regulation of removal of superoxide radicals GO:2000121 9.66 BMP7 CD36
48 common-partner SMAD protein phosphorylation GO:0007182 9.65 SMAD2 TGFB1
49 positive regulation of cell death GO:0010942 9.65 BMP7 CTGF
50 regulation of striated muscle tissue development GO:0016202 9.63 SMAD3 TGFB1

Molecular functions related to Renal Fibrosis according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.8 AGTR1 BMP6 HGF SMAD2 SMAD3 TGFB1
2 cytokine activity GO:0005125 9.76 BMP6 BMP7 CCL2 TGFB1
3 beta-catenin binding GO:0008013 9.7 CDH1 SMAD3 SMAD7
4 growth factor activity GO:0008083 9.55 BMP6 BMP7 CTGF HGF TGFB1
5 co-SMAD binding GO:0070410 9.51 SMAD2 SMAD3
6 I-SMAD binding GO:0070411 9.49 SMAD2 SMAD7
7 BMP receptor binding GO:0070700 9.43 BMP6 BMP7
8 R-SMAD binding GO:0070412 9.43 RGCC SMAD2 SMAD3
9 primary miRNA binding GO:0070878 9.4 SMAD2 SMAD3
10 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.37 SMAD2 SMAD3
11 type I transforming growth factor beta receptor binding GO:0034713 9.13 SMAD2 SMAD7 TGFB1
12 transforming growth factor beta receptor binding GO:0005160 9.02 BMP6 BMP7 SMAD2 SMAD3 TGFB1
13 protein binding GO:0005515 10.41 AGTR1 BMP7 CD36 CDH1 CTGF HGF

Sources for Renal Fibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....